Concepts (220)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 10 | 2023 | 296 | 2.680 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 11 | 2020 | 185 | 1.600 |
Why?
|
| Brachytherapy | 7 | 2023 | 120 | 1.310 |
Why?
|
| Chemoradiotherapy | 5 | 2020 | 306 | 1.140 |
Why?
|
| Breast Neoplasms | 15 | 2021 | 3022 | 1.140 |
Why?
|
| Radiotherapy Dosage | 9 | 2023 | 468 | 0.860 |
Why?
|
| Radiation Injuries | 5 | 2021 | 161 | 0.840 |
Why?
|
| Human papillomavirus 18 | 1 | 2020 | 16 | 0.700 |
Why?
|
| Endometrial Neoplasms | 3 | 2019 | 208 | 0.700 |
Why?
|
| Vaccines, DNA | 1 | 2020 | 18 | 0.700 |
Why?
|
| Human papillomavirus 16 | 1 | 2020 | 38 | 0.690 |
Why?
|
| Safety | 1 | 2020 | 145 | 0.660 |
Why?
|
| Cell Hypoxia | 1 | 2020 | 173 | 0.660 |
Why?
|
| Radiotherapy | 3 | 2016 | 332 | 0.610 |
Why?
|
| Radiometry | 2 | 2016 | 58 | 0.580 |
Why?
|
| Radiosurgery | 2 | 2021 | 287 | 0.570 |
Why?
|
| Cone-Beam Computed Tomography | 3 | 2020 | 64 | 0.500 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 262 | 0.460 |
Why?
|
| Female | 41 | 2024 | 46587 | 0.450 |
Why?
|
| Radiotherapy, Intensity-Modulated | 5 | 2016 | 173 | 0.430 |
Why?
|
| Radiation Oncology | 3 | 2019 | 122 | 0.430 |
Why?
|
| Radiotherapy, Conformal | 4 | 2020 | 82 | 0.430 |
Why?
|
| Adenocarcinoma | 2 | 2018 | 1185 | 0.420 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2018 | 1098 | 0.410 |
Why?
|
| Radiography, Thoracic | 1 | 2014 | 324 | 0.390 |
Why?
|
| Mastectomy, Segmental | 3 | 2011 | 101 | 0.370 |
Why?
|
| Lymph Nodes | 2 | 2016 | 550 | 0.370 |
Why?
|
| Middle Aged | 26 | 2024 | 26146 | 0.350 |
Why?
|
| Genital Neoplasms, Female | 2 | 2023 | 108 | 0.350 |
Why?
|
| Humans | 44 | 2024 | 89957 | 0.330 |
Why?
|
| Neoplasm Staging | 9 | 2021 | 2000 | 0.330 |
Why?
|
| Dietary Supplements | 1 | 2010 | 124 | 0.330 |
Why?
|
| Radiation Tolerance | 1 | 2010 | 173 | 0.320 |
Why?
|
| Aged | 22 | 2024 | 19254 | 0.320 |
Why?
|
| Sexism | 2 | 2019 | 54 | 0.320 |
Why?
|
| Skin | 3 | 2024 | 589 | 0.320 |
Why?
|
| Biological Products | 1 | 2010 | 160 | 0.290 |
Why?
|
| Aged, 80 and over | 13 | 2024 | 6783 | 0.280 |
Why?
|
| Prostheses and Implants | 1 | 2007 | 125 | 0.280 |
Why?
|
| Adult | 20 | 2024 | 26816 | 0.280 |
Why?
|
| Bone and Bones | 1 | 2007 | 271 | 0.270 |
Why?
|
| Prostate | 1 | 2010 | 407 | 0.260 |
Why?
|
| Organs at Risk | 2 | 2016 | 40 | 0.250 |
Why?
|
| Prostatic Neoplasms | 2 | 2021 | 1744 | 0.240 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2024 | 30 | 0.240 |
Why?
|
| Nocebo Effect | 1 | 2024 | 1 | 0.240 |
Why?
|
| Cisplatin | 3 | 2018 | 598 | 0.240 |
Why?
|
| Radiation, Ionizing | 1 | 2024 | 123 | 0.230 |
Why?
|
| Mammography | 1 | 2007 | 475 | 0.230 |
Why?
|
| Drugs, Generic | 1 | 2024 | 21 | 0.230 |
Why?
|
| Dysbiosis | 1 | 2024 | 81 | 0.220 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2021 | 290 | 0.210 |
Why?
|
| Mental Health | 1 | 2024 | 180 | 0.210 |
Why?
|
| Tumor Burden | 2 | 2017 | 310 | 0.210 |
Why?
|
| Anxiety | 1 | 2024 | 311 | 0.200 |
Why?
|
| Heart | 3 | 2018 | 578 | 0.190 |
Why?
|
| Young Adult | 7 | 2024 | 6409 | 0.190 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2021 | 58 | 0.190 |
Why?
|
| Hysterectomy | 2 | 2020 | 156 | 0.190 |
Why?
|
| Treatment Outcome | 10 | 2019 | 8273 | 0.180 |
Why?
|
| Standard of Care | 1 | 2021 | 65 | 0.180 |
Why?
|
| Rectum | 3 | 2016 | 148 | 0.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 2506 | 0.180 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2020 | 30 | 0.170 |
Why?
|
| Depression | 1 | 2024 | 512 | 0.170 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2020 | 33 | 0.170 |
Why?
|
| Carcinoma, Endometrioid | 2 | 2019 | 49 | 0.170 |
Why?
|
| Oximetry | 1 | 2020 | 82 | 0.170 |
Why?
|
| Multimodal Imaging | 1 | 2020 | 111 | 0.160 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 1131 | 0.160 |
Why?
|
| Dilatation | 1 | 2019 | 48 | 0.160 |
Why?
|
| Microbiota | 1 | 2024 | 407 | 0.160 |
Why?
|
| Hematologic Neoplasms | 1 | 2023 | 344 | 0.160 |
Why?
|
| Breast | 2 | 2011 | 292 | 0.160 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2020 | 2677 | 0.160 |
Why?
|
| Lymphatic Metastasis | 1 | 2020 | 495 | 0.160 |
Why?
|
| Physicians, Women | 1 | 2019 | 57 | 0.160 |
Why?
|
| Urethral Neoplasms | 1 | 2018 | 10 | 0.160 |
Why?
|
| Constriction, Pathologic | 1 | 2019 | 222 | 0.160 |
Why?
|
| Postoperative Care | 2 | 2017 | 231 | 0.150 |
Why?
|
| Breath Holding | 1 | 2018 | 23 | 0.150 |
Why?
|
| Methylprednisolone | 1 | 2018 | 64 | 0.150 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2018 | 30 | 0.150 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 338 | 0.150 |
Why?
|
| Vagina | 1 | 2019 | 177 | 0.150 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2020 | 300 | 0.140 |
Why?
|
| Thoracic Wall | 2 | 2014 | 25 | 0.140 |
Why?
|
| Retrospective Studies | 9 | 2021 | 9210 | 0.140 |
Why?
|
| Deoxycytidine | 1 | 2018 | 211 | 0.140 |
Why?
|
| Colon, Sigmoid | 1 | 2016 | 6 | 0.140 |
Why?
|
| Polycythemia Vera | 1 | 2016 | 23 | 0.140 |
Why?
|
| Urinary Bladder | 2 | 2016 | 248 | 0.140 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2018 | 151 | 0.140 |
Why?
|
| Drug Substitution | 1 | 2016 | 27 | 0.140 |
Why?
|
| Repressor Proteins | 1 | 2020 | 423 | 0.140 |
Why?
|
| Hydroxyurea | 1 | 2016 | 239 | 0.130 |
Why?
|
| Hyperlipidemias | 1 | 2016 | 92 | 0.130 |
Why?
|
| Patient Care Planning | 1 | 2016 | 84 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2023 | 889 | 0.130 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 608 | 0.130 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 2370 | 0.130 |
Why?
|
| Pyrazoles | 1 | 2016 | 150 | 0.130 |
Why?
|
| Lung | 2 | 2014 | 1292 | 0.130 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 376 | 0.120 |
Why?
|
| United States | 5 | 2021 | 7108 | 0.120 |
Why?
|
| Oxygen | 1 | 2020 | 745 | 0.120 |
Why?
|
| Radiotherapy Setup Errors | 1 | 2014 | 2 | 0.120 |
Why?
|
| Contrast Media | 1 | 2020 | 1084 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1352 | 0.120 |
Why?
|
| Hematologic Diseases | 1 | 2015 | 78 | 0.120 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 1704 | 0.120 |
Why?
|
| Databases, Factual | 2 | 2021 | 866 | 0.120 |
Why?
|
| Radiation Dosage | 2 | 2012 | 230 | 0.120 |
Why?
|
| Male | 13 | 2024 | 42674 | 0.110 |
Why?
|
| Patient Positioning | 1 | 2014 | 65 | 0.110 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 1243 | 0.110 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2015 | 306 | 0.110 |
Why?
|
| Disease-Free Survival | 2 | 2013 | 1169 | 0.110 |
Why?
|
| Data Interpretation, Statistical | 1 | 2014 | 303 | 0.100 |
Why?
|
| Equipment Design | 1 | 2014 | 422 | 0.100 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 377 | 0.100 |
Why?
|
| Surgical Instruments | 2 | 2014 | 57 | 0.100 |
Why?
|
| Hodgkin Disease | 1 | 2013 | 181 | 0.100 |
Why?
|
| Radiodermatitis | 1 | 2011 | 10 | 0.100 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2012 | 103 | 0.100 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 665 | 0.100 |
Why?
|
| Trigeminal Neuralgia | 1 | 2011 | 6 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 1055 | 0.090 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2011 | 15 | 0.090 |
Why?
|
| Colony-Forming Units Assay | 1 | 2010 | 40 | 0.090 |
Why?
|
| Fatigue | 2 | 2024 | 174 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 855 | 0.090 |
Why?
|
| Clinical Protocols | 1 | 2010 | 158 | 0.080 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2010 | 171 | 0.080 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2014 | 603 | 0.080 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 983 | 0.080 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 784 | 0.080 |
Why?
|
| Organ Specificity | 1 | 2010 | 277 | 0.080 |
Why?
|
| Time Factors | 2 | 2021 | 5358 | 0.080 |
Why?
|
| Obesity | 2 | 2014 | 972 | 0.080 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2007 | 160 | 0.070 |
Why?
|
| Adolescent | 4 | 2024 | 9339 | 0.070 |
Why?
|
| Epithelial Cells | 1 | 2010 | 689 | 0.060 |
Why?
|
| Cross Infection | 1 | 2007 | 151 | 0.060 |
Why?
|
| Cell Line | 1 | 2010 | 2495 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2018 | 2767 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2020 | 3475 | 0.060 |
Why?
|
| Wakefulness-Promoting Agents | 1 | 2024 | 1 | 0.060 |
Why?
|
| Placebo Effect | 1 | 2024 | 30 | 0.060 |
Why?
|
| Uncertainty | 1 | 2024 | 76 | 0.060 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 2586 | 0.060 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2024 | 251 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2010 | 1669 | 0.060 |
Why?
|
| Mastectomy | 2 | 2016 | 246 | 0.050 |
Why?
|
| Adaptation, Psychological | 1 | 2024 | 166 | 0.050 |
Why?
|
| Prospective Studies | 4 | 2014 | 4329 | 0.050 |
Why?
|
| Melphalan | 1 | 2023 | 98 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2018 | 1497 | 0.050 |
Why?
|
| Respiration | 2 | 2018 | 267 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2016 | 785 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 1862 | 0.050 |
Why?
|
| Child | 3 | 2024 | 7238 | 0.050 |
Why?
|
| Bacteria | 1 | 2024 | 486 | 0.040 |
Why?
|
| Prone Position | 1 | 2020 | 57 | 0.040 |
Why?
|
| Uterus | 1 | 2021 | 222 | 0.040 |
Why?
|
| Attention | 1 | 2024 | 395 | 0.040 |
Why?
|
| Scandinavian and Nordic Countries | 1 | 2019 | 8 | 0.040 |
Why?
|
| Women's Rights | 1 | 2019 | 7 | 0.040 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2019 | 22 | 0.040 |
Why?
|
| Age Factors | 1 | 2024 | 1880 | 0.040 |
Why?
|
| Body Mass Index | 2 | 2014 | 776 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2024 | 598 | 0.040 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2019 | 51 | 0.040 |
Why?
|
| Workflow | 1 | 2020 | 81 | 0.040 |
Why?
|
| Spirometry | 1 | 2018 | 68 | 0.040 |
Why?
|
| Vincristine | 1 | 2018 | 111 | 0.040 |
Why?
|
| Survival Rate | 2 | 2013 | 1899 | 0.040 |
Why?
|
| Prednisone | 1 | 2018 | 255 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2018 | 301 | 0.040 |
Why?
|
| Faculty, Medical | 1 | 2019 | 188 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2018 | 293 | 0.040 |
Why?
|
| Kinetics | 1 | 2019 | 1534 | 0.030 |
Why?
|
| Risk Factors | 2 | 2019 | 5558 | 0.030 |
Why?
|
| Nitriles | 1 | 2016 | 156 | 0.030 |
Why?
|
| Pelvis | 1 | 2016 | 96 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2016 | 387 | 0.030 |
Why?
|
| Lymphatic Irradiation | 1 | 2014 | 7 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2013 | 3678 | 0.030 |
Why?
|
| Rotation | 1 | 2014 | 91 | 0.030 |
Why?
|
| Gene Rearrangement | 1 | 2015 | 177 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2016 | 371 | 0.030 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2014 | 117 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2013 | 3770 | 0.030 |
Why?
|
| Acute Disease | 1 | 2015 | 846 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2016 | 1714 | 0.030 |
Why?
|
| Chicago | 1 | 2016 | 1434 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1082 | 0.020 |
Why?
|
| Comorbidity | 1 | 2015 | 953 | 0.020 |
Why?
|
| Age Distribution | 1 | 2011 | 199 | 0.020 |
Why?
|
| Organ Size | 1 | 2011 | 372 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 1603 | 0.020 |
Why?
|
| Vinblastine | 1 | 2010 | 100 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 899 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 591 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2010 | 221 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 2018 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2019 | 1062 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2011 | 332 | 0.020 |
Why?
|
| Carboplatin | 1 | 2010 | 312 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2010 | 549 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2013 | 1866 | 0.020 |
Why?
|
| Quality of Life | 1 | 2016 | 1682 | 0.020 |
Why?
|
| Biomarkers | 1 | 2014 | 1778 | 0.020 |
Why?
|
| Esthetics | 1 | 2007 | 45 | 0.020 |
Why?
|
| Pakistan | 1 | 2007 | 15 | 0.020 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2007 | 76 | 0.020 |
Why?
|
| Movement | 1 | 2007 | 313 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2007 | 848 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2007 | 398 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 2331 | 0.010 |
Why?
|